Resources
- sort by:
- Relevance
- Date
- Popularity
- Geron Enters into a Collaboration and License Agreement with MERCK & CO., INC. for Cancer Vaccines Targeting Telomerase
- MENLO PARK, Calif. -- Geron Corporation (Nasdaq:GERN) announced today it has entered into a collaboration and license agreement with Merck & Co., Inc. (NYSE:MRK) to develop a cancer vaccine targeting telomerase utilizing Merck's expertise in vaccine technologies.
- Research articles 2005-07-18
- Acumen Pharmaceuticals Announces Amended Agreement with Merck to Include Exclusive Diagnostic Rights
- SOUTH SAN FRANCISCO, Calif. -- Acumen Pharmaceuticals, a leading pre-clinical biotech company working in Alzheimer's therapeutics, today announced that it has amended its existing license agreement with Merck & Co., Inc. to grant an exclusive license to research and develop amyloid-derived diffusible ligand ADDL directed diagnostic products.
- Research articles 2006-11-27
- Celera and Merck Sign Technology License Agreement
- Business Editors Merck & Co., Inc. (NYSE:MRK) announced today that it had signed a license agreement with Celera Genomics Group (NYSE:CRA), an Applera Corporation business, under which Merck has access to Celera's proprietary human and mouse genome databases. Financial terms of the agreement were not disclosed. The...
- Research articles 2002-07-09
- Merck & Co., Inc. and Cardiome Pharma Corp. sign a collaboration and license agreement for the development and commercialization of vernakalant, an investigational candidate for the treatment of atrial fibrillation.(INDUSTRIAL Briefs)
- Merck & Co., Inc. and Cardiome Pharma Corp. sign a collaboration and license agreement for the development and commercialization of vernakalant, an investigational candidate for the treatment of atrial fibrillation. The agreement provides Merck with exclusive global rights to the oral formulation of vernakalant...
- Research articles 2009-05-01
- Dyax Corp. and Merck KGaA Enter Into License Agreement for Discovery of Therapeutic Antibodies and Peptides
- CAMBRIDGE, Mass. -- Dyax Corp. (Nasdaq: DYAX) announced today that it has granted a non-exclusive license to its proprietary phage display libraries to Merck KGaA (Darmstadt, Germany) for the discovery and development of therapeutic antibodies and peptides. Under the terms of the agreement, Dyax receives an upfront technology license fee...
- Research articles 2005-08-18
- Merck & Co., Inc. and Cardiome Sign License Agreement for Vernakalant, an Investigational Drug for Treatment of Atrial Fibrillation
- WHITEHOUSE STATION, N.J. & VANCOUVER -- Merck & Co., Inc. and Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced a collaboration and license agreement for the development...
- Research articles 2009-04-08
- Ono Pharmaceutical Co., Ltd. Signs Agreement Granting Merck & Co., Inc. Worldwide License for the Injectable Formulation of ONO-2506, a Novel Compound for Stroke
- OSAKA, JAPAN & WHITEHOUSE STATION, N.J. -- Ono Pharmaceutical Co., Ltd. and Merck & Co., Inc. today announced that they have signed an agreement granting Merck the worldwide license for ONO-2506 (R-(-)-2-propyloctanoic acid), a novel intravenous compound currently in Phase II development for the treatment of acute stroke. Stroke is...
- Research articles 2004-11-10
- Celera Grants License to Merck & Co., Inc. for Cancer Targets
- ALAMEDA, Calif. -- Celera (NYSE:CRA), an Applera Corporation business, today announced a two year exclusive license agreement with Merck & Co., Inc. providing Merck with access to up to ten cancer targets for the development of RNA interference-RNAi based therapeutics. These therapeutic targets are over-expressed on the surface of several...
- Research articles 2008-04-10
- Sumitomo Pharmaceuticals Signs Agreement with Merck & Co., Inc. Forming Global Partnership for SM13496 , an Atypical Antipsychotic Compound
- TOKYO & WHITEHOUSE STATION, N.J. -- Sumitomo Pharmaceuticals Co., Ltd. and Merck & Co., Inc. today announced that they have signed an agreement to collaborate on SM13496 lurasidone, an atypical antipsychotic compound currently in Phase II development for the treatment of schizophrenia, one of the most chronic and disabling of...
- Research articles 2005-07-05
- Stratagene and Merck Subsidiary, Rosetta Inpharmatics, Enter into Joint Development and License Agreement; Companies Will Develop RNA Purification System for Use in Molecular Diagnostics and Research Applications
- LA JOLLA, Calif. -- Stratagene Corporation (Nasdaq:STGN), a developer, manufacturer and marketer of specialized life science research and diagnostics products, announced today that it has entered into a joint development and license agreement with Rosetta Inpharmatics LLC, a wholly-owned subsidiary of Merck & Co., Inc., to create an automated solution...
- Research articles 2006-08-14
- SurModics and Merck Announce Entering an Ophthalmic License and Research Collaboration Agreement.
- M2 PRESSWIRE-28 June 2007-Upward Momentum: SurModics and Merck Announce Entering an Ophthalmic License and Research Collaboration AgreementC1994-2007 M2 COMMUNICATIONS LTD RDATE:28062007 Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay a step ahead...
- Research articles 2007-06-28
- Stratagene entered into a joint development and license agreement with Rosetta Inpharmatics, a unit of Merck & Co., to create an automated solution for the isolation of nucleic acids from a variety of clinical samples
- Stratagene entered into a joint development and license agreement with Rosetta Inpharmatics, a unit of Merck & Co., to create an automated solution for the isolation of nucleic acids from a variety of clinical samples. The instrument and single-use consumables will be manufactured and commercialized by Stratagene.
- Research articles 2006-10-15
- Merck and Paratek Pharmaceuticals Sign Collaboration Agreement for Novel Antibiotic PTK 0796 Currently in Phase 1 Testing
- WHITEHOUSE STATION, N.J. & BOSTON -- Merck & Co., Inc. and Paratek Pharmaceuticals, Inc. announced today that Paratek has entered into an exclusive, worldwide collaborative development and license agreement with Merck --through an affiliate -- for PTK 0796, a novel, broad-spectrum aminomethylcycline AMC antibiotic with oral and intravenous IV formulations...
- Research articles 2006-03-09
- Cubist Pharmaceuticals Licenses Rights for Development and Commercialization of CUBICIN in Japan to Merck & Co., Inc
- LEXINGTON, Mass. -- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it has entered into a license agreement with Merck & Co., Inc. for the development and commercialization of CUBICIN[R] daptomycin for injection in Japan. Merck will develop and commercialize CUBICIN through its wholly-owned subsidiary, Banyu Pharmaceutical Co., Ltd. With...
- Research articles 2007-03-22
- MethylGene Signs Worldwide Agreement With Merck-Frosst Canada & Co. on Antibiotic and Antibiotic Resistance Program.
- MONTREAL, QUEBEC, Jun 24, 2003 CCNMatthews via COMTEX MethylGene Inc., a private Canadian drug discovery and development company is pleased to announce today that it has entered into a worldwide license, research, development, and commercialization agreement with Merck-Frosst Canada & Co. on a small...
- Research articles 2003-06-24
- Addex Achieves First Milestone in Parkinson's Disease Collaboration with Merck & Co., Inc.
- Allosteric modulation company Addex Pharmaceuticals (SWX: ADXN) announced today that the first preclinical milestone has been achieved in a recently announced exclusive collaboration and license agreement with Merck & Co., Inc. (through its affiliate Merck Sharp & Dohme...
- Research articles 2008-02-25
- Addex Achieves First Milestone in Parkinson's Disease Collaboration With Merck & Co., Inc.
- Allosteric modulation company Addex Pharmaceuticals (SWISS: ADXN) announced today that the first preclinical milestone has been achieved in a recently announced exclusive collaboration and license agreement with Merck & Co., Inc. (through its affiliate Merck Sharp & Dohme Research Ltd). The collaboration is focused on developing an emerging class of...
- Research articles 2008-02-25
- Neuromed Pharmaceuticals and Merck & Co., Inc. Announce Agreement for Novel N-type Calcium Channel Compounds
- CONSHOHOCKEN, Pa. & WHITEHOUSE STATION, N.J. -- Neuromed Pharmaceuticals Ltd. and Merck & Co., Inc. announced today that they have signed a research collaboration and license agreement to research, develop and commercialize novel compounds for the treatment of pain and other neurological disorders, including Neuromed's lead compound, NMED-160, which is...
- Research articles 2006-03-20
- ImClone Systems and Merck KGaA Amend and Supplement ERBITUX Agreement
- NEW YORK -- ImClone Systems Incorporated (NASDAQ: IMCL) and Merck KGaA, Darmstadt, Germany, announced today that they have entered into agreements amending and supplementing the 1998 development and license agreement covering ERBITUXR and certain other work in the field of EGFR-targeted antibodies.
- Research articles 2006-07-20
- IMCLONE SYSTEMS AND MERCK KGaA EXTEND COLLABORATION FOR THERAPEUTIC CANCER VACCINES
- NEW YORK--BUSINESS WIRE--May 16, 1996--ImClone Systems Incorporated (Nasdaq: IMCL) today announced that it has extended its collaboration with Merck KGaA for the development of therapeutic cancer vaccines, specifically BEC-2, an anti-idiotypic vaccine, for use in small cell lung carcinoma and malignant melanoma. The collaboration continues a research and license...
- Research articles 1996-05-16
- << Previous
- page 1 of 2
- Next >>
Presented by American Express